Agenus (AGEN) Competitors

Myriad Genetics (NASDAQ:MYGN) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Do insiders and institutionals hold more shares of MYGN or AGEN?

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 2.4% of Myriad Genetics shares are held by insiders. Comparatively, 5.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is MYGN or AGEN more profitable?

Myriad Genetics has a net margin of -47.45% compared to Agenus' net margin of -167.52%. Agenus' return on equity of 0.00% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-47.45%	-5.17%	-3.44%
Agenus	-167.52%	N/A	-81.04%

Do analysts prefer MYGN or AGEN?

Myriad Genetics presently has a consensus target price of $12.45, suggesting a potential upside of 106.89%. Agenus has a consensus target price of $15.50, suggesting a potential upside of 242.92%. Given Agenus' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Agenus	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media favor MYGN or AGEN?

In the previous week, Myriad Genetics had 8 more articles in the media than Agenus. MarketBeat recorded 12 mentions for Myriad Genetics and 4 mentions for Agenus. Myriad Genetics' average media sentiment score of 0.30 beat Agenus' score of 0.27 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Agenus	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, MYGN or AGEN?

Myriad Genetics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Which has stronger earnings and valuation, MYGN or AGEN?

Myriad Genetics has higher revenue and earnings than Agenus. Myriad Genetics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$832.90M	0.67	-$127.30M	-$4.28	-1.41
Agenus	$101.71M	1.42	-$227.21M	-$7.15	-0.63

Summary

Myriad Genetics beats Agenus on 10 of the 16 factors compared between the two stocks.